Study Summary
Long-term follow-up of subjects who received SB-318, SB-913, or SB-FIX in a previous trial and completed at least 52 weeks post-infusion follow-up in their primary protocol. Enrolled subjects will be followed for a total of up to 10 years following exposure to SB-318, SB-913, or SB-FIX.
Want to learn more about this trial?
Request More InfoInterventions
SB-318BIOLOGICAL
No study drug is administered in this study. Subject who received SB-318 in a previous trial will be evaluated in this trial for long-term safety.
SB-913BIOLOGICAL
No study drug is administered in this study. Subject who received SB-913 in a previous trial will be evaluated in this trial for long-term safety.
SB-FIXBIOLOGICAL
No study drug is administered in this study. Subject who received SB-FIX in a previous trial will be evaluated in this trial for long-term safety.
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| UCSF Benioff Children's Hospital Oakland | Oakland | California | United States |
| Ann & Robert H. Lurie Children's Hospital of Chicago | Chicago | Illinois | United States |
| New York University Grossman School of Medicine | New York | New York | United States |
| University of North Carolina | Chapel Hill | North Carolina | United States |
| Cincinnati Children's Hospital Medical Center | Cincinnati | Ohio | United States |